Portal de Periódicos da CAPES

Adverse effects and other safety aspects of the hepatitis C antivirals

2000; Wiley; Volume: 15; Issue: s2 Linguagem: Inglês

10.1046/j.1440-1746.2000.02114.x

1440-1746

Anuchit Chutaputti,

Hepatitis B Virus Studies

Journal of Gastroenterology and HepatologyVolume 15, Issue s2 p. E156-E163 Adverse effects and other safety aspects of the hepatitis C antivirals Anuchit Chutaputti, Anuchit Chutaputti Pramongkutklao Hospital, Rajathevee, Bangkok, ThailandSearch for more papers by this author Anuchit Chutaputti, Anuchit Chutaputti Pramongkutklao Hospital, Rajathevee, Bangkok, ThailandSearch for more papers by this author First published: 04 January 2002 https://doi.org/10.1046/j.1440-1746.2000.02114.xCitations: 41 Correspondence: DrAnuchitChutaputti Pramongkutklao Hospital, 315 Rajavithi Road, Rajathevee, Bangkok 10400, Thailand, E-mail: [email protected] Read the full textAbout ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (Suppl. 1): S112 21. 2 Renault PF & Hoofnagle JH. Side effects of alpha interferon. Semin. Liver Dis. 1989; 9: 273 7. 3 Fattovich G, Giustina G, Favarato S et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996; 24: 38 47. 4 Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501 6. 5 Michael FW & Hoofnagle JH. Therapy of hepatitis C. Semin. Liver Dis. 1995; 15: 82 90. 6 De Salvo L, Plumacher Z, Gomez O et al. Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia. Invest. Clin. 1996; 37: 177 81. 7 Ruiz-Moreno M, Carreno V, Rua MJ et al. Increase in triglycerides during alpha-interferon treatment of chronic viral hepatitis (Letter). J. Hepatol. 1992; 16: 384. 8 Berruti A, Gorzegno G, Vitetta G et al. Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment: a case report. Tumori 1992; 78: 353 5. 9 Bory E, Garcia Rico A, Pedro-Botet J et al. Severe hypertriglyceridemia during the course of treatment with interferon-alpha in a patient with chronic hepatitis C (Letter). Gastroenterol. Hepatol. 1996; 19: 542. 10 Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996; 25: 283 91. 11 Tada H, Saitoh S, Nagakawa Y et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J. Gastroenterol. 1996; 31: 582 4. 12 Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 1987; 147: 1577 80. 13 La Civita L, Zignego AL, Lombardini F et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J. Rheumatol. 1996; 23: 1641 3. 14 Konishi T. A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C. Rinsho Shinkeigaku (Clin. Neurol.) 1996; 36: 980 5. 15 Merimsky O & Chaitchik S. Neurotoxicity of interferon-alpha. Anti-Cancer Drugs 1992; 3: 567 70. 16 Merimsky O, Nisipeanu P, Loewenstein A et al. Interferon-related cortical blindness. Cancer Chemother. Pharmacol. 1992; 29: 329 30. 17 Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. J. Hepatol. 1996; 24: 48 51. 18 Janssen HLA, Berk L, Vermeulen M et al. Seizures associated with low-dose α-interferon (Letter). Lancet 1990; 336: 1580. 19 Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908 16. 20 Hoofnagle JH, Di Bisceglie AM, Waggoner JG et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116 21. 21 Janssen HL, Brouwer JT, Nevens F et al. Fatal hepatic decompensation associated with interferon alfa: European concerted action on viral hepatitis (Eurohep). BMJ 1993; 306: 107 8. 22 Vento S, Di Perri G, Garofano T et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis (Letter). Lancet 1989; 2: 926. 23 Garcia-Buey L, Garcia-Monzon C, Rodriguez S et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770 7. 24 Todros L, Saracco G, Durazzo M et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology 1995; 22: 1374 8. 25 Farhat BA, Johnson PJ, Williams R. Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. J. Hepatol. 1994; 20: 560 1. 26 Heathcote EJ. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy. Gastroenterology 1995; 108: 1942 4. 27 Cianciara J & Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig. Dis. Sci. 1995; 40: 1842 4. 28 Ruiz-Moreno M, Rua MJ, Carreno V et al. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children (Letter). J. Hepatol. 1991; 12: 165 6. 29 Noda K, Enomoto N, Arai K et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 1996; 31: 716 22. 30 Mayet WJ, Hess G, Garken G et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24 8. 31 Fonseca V, Thomas M, Dusheiko G. Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinol. 1991; 125: 491 3. 32 Preziati D, La Rosa L, Covini G et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur. J. Endocrinol. 1995; 132: 587 93. 33 Carella C, Amato G, Biondi B et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-α therapy for HCV chronic hepatitis. Horm. Res. 1995; 44: 110 4. 34 Marcellin P, Pouteau M, Renard P et al. Sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. Gut 1992; 33: 855 6. 35 Lisker-Mekman M, Di Bisceglie AM, Usala SJ et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155 60. 36 Regulatory Affairs. Study Monitoring Data. Thousand Oaks, CA: Amgen, 1997. 37 Watanabe U, Hashimoto E, Hisamitsu T et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am. J. Gastroenterol. 1994; 89: 399 403. 38 Chung YW & Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am. J. Gastroenterol. 1993; 88: 244 7. 39 Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-α therapy. Clin. Endocrinol. 1996; 44: 635 42. 40 Baudin E, Marcellin P, Pouteau M et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 1993; 39: 657 61. 41 Barbolla L, Paniagua C, Outeirino J et al. Haemolytic anaemia to the alpha-interferon treatment: a proposed mechanism. Vox Sang. 1993; 65: 156 7. 42 Yanaihara H, Nakazono M, Tsunoda S. A case of drug-induced immune hemolytic anemia during alpha-interferon therapy for renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi (Jpn J. Urol.) 1996; 87: 714 17 (in Japanese). 43 Stern SC, Asagba GO, Hegde UM. Prolonged thrombocytopenia following alpha-interferon for refractory immune thrombocytopenic purpura. Clin. Lab. Haematol. 1994; 16: 183 5. 44 Cavanna L, Vallisa D, Berte R et al. Severe immune thrombocytopenic purpura relapse after alpha-interferon in chronic myeloid leukemia, successfully treated with cyclosporine (Letter). Am. J. Hematol. 1994; 47: 255 6. 45 Mehta ND, Hooberman AL, Vokes EE et al. A 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy (Letter). Am. J. Hematol. 1992; 41: 141. 46 Schilling PJ, Kurzrock R, Kantarjian H et al. Development of systemic lupus erythematosus after interferon therapy for chronic myologenous leukemia. Cancer 1991; 68: 1536 7. 47 Tolaymat A, Leventhal B, Sakarcan A et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J. Pediatr. 1992; 120: 429 32. 48 Waguri M, Hanafusa T, Itoh N et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res. Clin. Pract. 1994; 23: 33 6. 49 Fabris P, Betterle C, Floreani A et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis (Letter). Lancet 1992; 340: 548. 50 Foulis AK. Interferon-alpha and IDDM (Letter & Comment). Diabetologia 1996; 39: 127. 51 Maeda T, Onishi S, Miura T et al. Exacerbation of primary biliary cirrhosis during interferon-α2b therapy for chronic active hepatitis C. Dig. Dis. Sci. 1995; 40: 1226 30. 52 Noda K, Enomoto N, Aria K et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 1996; 31: 716 22. 53 Di Cesare E, Previti M, Russo F et al. Interferon-α therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig. Dis. Sci. 1996; 41: 1672 7. 54 Imagawa I, Itoh N, Hanafusa T et al. Autoimmune endocrine disease induced by recombinant interferon-α therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metab. 1995; 80: 922 6. 55 Coroneos E, Truong L, Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am. J. Kidney Dis. 1997; 29: 132 5. 56 Coroneos E, Petrusevska G, Varghese F et al. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am. J. Kidney Dis. 1996; 28: 888 92. 57 Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 1995; 47: 1412 18. 58 Teragawa H, Hondo T, Amano H et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996; 37: 905 15. 59 Sartori M, Andorno S, La Terra G et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur. J. Clin. Invest. 1995; 25: 68 70. 60 Simsek H, Savas C, Akkiz H et al. Interferon-induced vitiligo in a patients with chronic viral hepatitis C infection. Dermatology 1996; 193: 65 6. 61 Bernstein D, Reddy KR, Jeffers L et al. Canities and vitiligo complicating interferon therapy for hepatitis C. Am. J. Gastroenterol. 1995; 90: 1176 7. 62 Areias J, Velho GC, Cerqueira R et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur. J. Gastroenterol. Hepatol. 1996; 8: 825 8. 63 Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104: 903 5. 64 Funk J, Langeland T, Schrumpf E et al. Psoriasis induced by interferon-alpha. Br. J. Dermatol. 1991; 125: 463 5. 65 Makino Y, Tanaka H, Nakamura K et al. Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. J. Rheumatol. 1994; 21: 1771 2. 66 Lombardini F, Taglione E, Riente L et al. Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. Scand. J. Rheumatol. 1997; 26: 58 60. 67 Georgetson MJ, Yarze JC, Lalos AT et al. Exacerbation of psoriasis due to interferon-α treatment of chronic active hepatitis. Am. J. Gastroenterol. 1993; 88: 1756 8. 68 Kawano T, Shigehira M, Uto H et al. Retinal complications during interferon therapy for chronic hepatitis C. Am. J. Gastroenterol. 1996; 91: 309 13. 69 Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch. Ophthalmol 1995; 113: 1041 4. 70 Kanda Y, Shigeno K, Kinoshita N et al. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134 5. 71 Chin K, Tabata C, Satake N et al. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105: 939 41. 72 Yufu Y, Yamashita S, Nishimura J et al. Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia (Letter). Am. J. Hematol. 1994; 47: 253. 73 Hizawa N, Kojima J, Kojima T et al. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern. Med. 1994; 33: 337 41. 74 Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose/ tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon and interferon alfa-2a to healthy subjects. Hepatology 1998; 28: 702A. 75 Patterson JL & Fernandez-Larson R. Molecular action of ribavirin. Rev. Infect. Dis. 1990; 12: 1132 46. 76 Bodenheimer HcJr, Linsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473 7. 77 McHutchison JG & Poynard T. Combination therapy with interferon alfa and ribavirin as retreatment of chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 57 65. 78 Poynard T, Marcellin P, Lee S et al. An international randomized trial of interferon alfa-2b and ribavirin (intron A/rebetol) 48 or 24 weeks vs intron A 48 weeks for first line treatment of chronic hepatitis C. Hepatology 1998; 28: 387A. 79 McHutchison J, Gordon S, Schiff E et al. Interferon alfa 2b alone or in combination with ribavirin in naïve chronic HCV patients: a US multicenter trial. Hepatology 1998; 28: 387A. 80 Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1493 9. 81 McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485 92. 82 Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426 32. 83 Barbaro G, Lorenzo G, Soldini M et al. Interferon alfa-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon alfa alone: an Italian multicenter, randomized, controlled, clinical study, Am. J. Gastroenterol. 1998; 93: 2445 51. 84 Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers. J. Hepatol. 1997; 26: 961 6. 85 Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferonα-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83 7. 86 Reichard O, Norkrans G, Fryden A et al. Adding ribavirin to interferon alfa-2b for chronic hepatitis C infection increased virological response and nausea. Gut 1998; 43: 602. 87 Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naïve patients. Semin. Liver Dis. 1999; 19 (Suppl. 1): 67 75. 88 Deep LS, Khouri AS, Hall CE et al. Interferon and ribavirin associated retinopathy in patients with hepatitis C. Hepatology 1998; 28: 371A. 89 EASL. International Consensus Conference on Hepatitis C. J. Hepatol. 1999; 30: 956 61. Citing Literature Volume15, Issues2May 2000Pages E156-E163 ReferencesRelatedInformation